MRNA Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 8.69%. Moderna, Inc.'s return on equity of -29.19% beat Bristol Myers Squibb Co.'s return on equity of 39.9%.

Moderna, Inc. has a consensus price target of $41.60, signalling downside risk potential of -10.73%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $59.91 which suggests that it could grow by 0.31%. Given that Bristol Myers Squibb Co. has higher upside potential than Moderna, Inc., analysts believe Bristol Myers Squibb Co. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.318, which suggesting that the stock is 31.821% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.296%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.17% to investors and pays a quarterly dividend of $0.63 per share. Moderna, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 71.98% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.5B. Moderna, Inc.'s net income of -$826M is lower than Bristol Myers Squibb Co.'s net income of $1.1B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 17.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 9.32x versus 2.53x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 34.4%. Moderna, Inc.'s return on equity of -29.19% beat Eli Lilly & Co.'s return on equity of 104.39%.

Moderna, Inc. has a consensus price target of $41.60, signalling downside risk potential of -10.73%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,202.37 which suggests that it could grow by 17.82%. Given that Eli Lilly & Co. has higher upside potential than Moderna, Inc., analysts believe Eli Lilly & Co. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.318, which suggesting that the stock is 31.821% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Moderna, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Moderna, Inc.'s net income of -$826M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 45.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 9.32x versus 14.26x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 18.06%. Moderna, Inc.'s return on equity of -29.19% beat Merck & Co., Inc.'s return on equity of 39.63%.

Moderna, Inc. has a consensus price target of $41.60, signalling downside risk potential of -10.73%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.65%. Given that Merck & Co., Inc. has higher upside potential than Moderna, Inc., analysts believe Merck & Co., Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.318, which suggesting that the stock is 31.821% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Moderna, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Moderna, Inc.'s net income of -$826M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 9.32x versus 4.69x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of -9.34%. Moderna, Inc.'s return on equity of -29.19% beat Pfizer Inc.'s return on equity of 10.84%.

Moderna, Inc. has a consensus price target of $41.60, signalling downside risk potential of -10.73%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 4.9%. Given that Pfizer Inc. has higher upside potential than Moderna, Inc., analysts believe Pfizer Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.318, which suggesting that the stock is 31.821% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.28% to investors and pays a quarterly dividend of $0.43 per share. Moderna, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Moderna, Inc.'s net income of -$826M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 9.32x versus 2.49x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.